Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

NEW YORK--(BUSINESS WIRE)-- #Cassava--Second paragraph of release dated December 3, 2021, should read: The lawsuit alleges that... (instead of The complaint, filed on January 5, 2021, alleges that...) The updated release reads:  CASSAVA SCIENCES ALERT: BRAGAR EAGEL & SQUIRE, P.C. IS INVESTIGATING CASSAVA SCIENCES, INC. ON BEHALF OF LONG-TERM STOCKHOLDERS AND ENCOURAGES INVESTORS TO CONTACT THE FIRM Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating p

CORRECTING and REPLACING CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Cassava--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA) on behalf of long-term stockholders following a class action complaint that was filed against Cassava Sciences on August 27, 2021. Our investigation concerns whether the board of directors of Cassava Sciences have breached their fiduciary duties to the company. The complaint, filed on January 5, 2021, all

CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

If you can stomach the volatility, you may want to enter an appropriately-sized position in SAVA stock. The post While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential appeared first on InvestorPlace.

While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential

The investigation really isn't the underlying concern.

Should Investors Worry About the Federal Investigation of Cassava?

Cassava Sciences has been one of 2021's best stocks. We can learn some things from Cassava to help us find the next great biotech or growth & innovation stock.

Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing

There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease. The post Cassava Sciences Just Returned to the Buy Zone appeared first on InvestorPlace.

Cassava Sciences Just Returned to the Buy Zone

The stock price of Cassava Sciences plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental Alzheimer's treatment - Simufilam. [1] SAVA stock saw a large fall in September following a citizen petition filed to.

Will Cassava Sciences Stock Continue To See Lower Levels?

Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease.  The second Phase 3 study is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 78 weeks over 78 weeks in approximately 1,000 patients.

Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam

Cassava Sciences is a company with a promising Alzheimer's Drug candidate. The FDA has a process called accelerated approval that allows for drugs to be approved for use before the finishing of drug trials.

Is An Accelerated Approval Likely For Cassava Sciences?

Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.

Cassava (SAVA) Down on Report of SEC Investigation Into AD Program

Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of Simufilam Over 78 Weeks in 1,000 Patients with Alzheimer's Disease Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of Simufilam Over 78 Weeks in 1,000 Patients with Alzheimer's Disease

Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer's Disease

BioNTech SE

Ocugen, Inc.

3 Biotech Stocks That Have More Than Tripled so far This Year

The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for its experimental Alzheimer's drug simufilam. The report comes just two days after Cassava, in an SEC filing, revealed that “certain government agencies” had asked the Company for documentation.

See Why Cassava Sciences Shares Are Falling On Wednesday?

Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten.

Why Cassava Sciences Is Sliding Lower Today

Cassava Sciences (SAVA) stock is on the move Wednesday as investors react to reports of an SEC investigation over possible data manipulation. The post SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today appeared first on InvestorPlace.

SAVA Stock Alert: The SEC Investigation That Has Cassava Sciences Cratering Today

Big 5 Sporting Goods

Gogo

iRobot

Lemonade

iStar

ZoomInfo Technologies

Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. The post 7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside appeared first on InvestorPlace.

7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside

Biogen

Neurological diseases including Alzheimer's are a huge unmet need that BIIB and SAVA are working on solutions for. BIIB's diversification, low sentiment, and profitability make it more suitable to a wider audience of investors.

Biogen Vs. Cassava Sciences Stock: Which Is The Better Buy?

The company's Q3 earnings "missed" expectations which is laughable. Cassava is increasing spending to get its phase 3 trials off the ground.

Cassava Sciences: Cash Is King

Annovis Bio

Anavex Life Sciences

Eli Lilly

Prothena

An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the third quarter ended September 30, 2021. Net loss for the third quarter ended September 30, 2021, was $9.6 million, or $0.24 per share, compared to a net loss of $1.4 million, or $0.06 per share, for the same period in 2020. Net cash used in operations was $22.2 million during the first nine months of 2021. Net cash use for operations for full-year 2021 is expected to be approximately $25 to $30 million, up from previous guidance of $20 to $25 million due to a significant prepayment made to a contract research organization for our Phase 3 clinical program with simufilam. An additional $22.0 million was used during the third quarter of 2021 for an all-cash purchase of an office complex in Austin, Texas, which will serve as the Company's future corporate headquarters. Cash and cash equivalents were $241.5 million as of September 30, 2021, with no debt.

Cassava Sciences Reports Third Quarter 2021 Financial Results

Cassava stock increased 49% last Thursday as a short attack fell on deaf ears in favor of a positive report from the Journal of Neuroscience.

Cassava Sciences Stock: Top Contender For A Continued Short Squeeze

Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. The post Cassava Sciences Needs Time and Data to Prove Itself Before You Buy appeared first on InvestorPlace.

Cassava Sciences Needs Time and Data to Prove Itself Before You Buy

After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. The post Cassava Is a Sell After Accusations of Data Manipulation appeared first on InvestorPlace.

Cassava Is a Sell After Accusations of Data Manipulation

Central to Cassava's hypothesis requires amyloid beta-42 to induce an altered conformation of structural protein filamin A and that sumifilam restores altered filmin A back to its native state. Researchers have demonstrated that mutations that cause familial AD, amyloid beta-40, and -42 production is more likely to be reduced or abolished due to decreased enzymatic activity of gamma-secretase.

Cassava Sciences' Hypothesis Raises Doubts

Corcept Therapeutics

Novo Nordisk

Regeneron Pharmaceuticals

Check out these biotech stocks that could prove to be valuable additions to your portfolio.

News for Cassava Sciences Inc Stock (SAVA)